Journal Scans
Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
EGFR Testing Necessary for All Patients With NSCLC
SP D'Angelo, MC Pietanza, ML Johnson, GJ Riely, VA Miller, CS Sima, MF Zakowski, VW Rusch, M Ladanyi, MG Kris
Yes
20110311
2011 Apr 11
J Clin Oncol
Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
J Clin Oncol. 2011 Apr 11;[Epub Ahead of Print], SP D'Angelo, MC Pietanza, ML Johnson, GJ Riely, VA Miller, CS Sima, MF Zakowski, VW Rusch, M Ladanyi, MG Kris
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Patients with lung adenocarcinoma that have epidermal growth factor receptor (EGFR) mutations in exon 19 or 21 are more likely to respond to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib than those without these EGFR mutations. Since these mutations are more common in never smokers and women, many physicians prescribe TKIs at diagnosis to all never smokers and order EGFR testing only for women never smokers. However, studies have shown that EGFR mutations are also found in men and...
